Hong Kong Gas Utilities Stock News

Shanghai Chicmax Cosmetic (SEHK:2145) issued unaudited guidance for 2025, projecting revenue of RMB 9,100.0 million to RMB 9,200.0 million and profit of RMB 1,140.0 million to RMB 1,160.0 million, highlighting momentum across its key brands. See our latest analysis for Shanghai Chicmax Cosmetic. The upbeat 2025 guidance sits against a mixed share price backdrop, with a 7% 1 day share price return and a 1 year total shareholder return of 68.27%. At the same time, the 90 day share price return...

JD Health’s latest earnings and why they matter JD Health International (SEHK:6618) has just reported its full year 2025 results, with sales of CNY 73,441.49 million and net income of CNY 5,375.41 million, catching investor attention. See our latest analysis for JD Health International. JD Health International’s full year earnings arrive at a time when the 1-year total shareholder return of 35.38% contrasts with a 20.20% 30-day share price decline and a 19.60% 90-day share price decline,...

CK Asset Holdings (SEHK:1113) has set a date for its next key catalyst, with the board scheduled to meet in Hong Kong on 19 March 2026 to approve the 2025 annual results and consider a final dividend. See our latest analysis for CK Asset Holdings. At a share price of HK$47.9, CK Asset Holdings has seen a 30 day share price return of 4.27% and a 90 day share price return of 17.40%, with a 1 year total shareholder return of 42.02%. This performance may lead some investors to reassess the stock...

Dividend announcements put Shangri-La Asia in focus Shangri-La Asia (SEHK:69) has drawn investor attention after announcing a final single tier dividend of HK$0.06 per share for FY2025, together with a proposed THB0.50 per share payout pending shareholder approval. The Hong Kong dollar dividend is scheduled for payment on June 29, 2026, with an ex dividend date of June 9 and an entitlement date of June 10, while the Thai baht proposal totals THB65 million. See our latest analysis for...

How Prada (SEHK:1913) Just Performed Prada (SEHK:1913) has released its FY 2025 numbers with first half revenue at €2.7 billion and basic EPS of €0.15, setting the tone for how the rest of the year may shape up for the luxury group. The company has seen revenue move from €2.5 billion and EPS of €0.15 in 1H 2024 to €2.7 billion and EPS of €0.18 in 2H 2024, finishing the trailing twelve months with €5.7 billion of revenue and EPS of €0.33. With a trailing net profit margin of 14.9% and growth...

Allied Group (SEHK:373) is in focus after the board announced that long serving executive director Mr. Edwin Lo King Yau will retire. Director of investment Mr. Mark Wong Tai Chun will assume board and representative roles. See our latest analysis for Allied Group. The leadership reshuffle comes after a strong run in the shares, with Allied Group’s 30 day share price return of 16.26% and 90 day share price return of 50.67%, while its 1 year total shareholder return of 131.72% suggests recent...

What Pop Mart’s recent share performance tells you With no single headline event driving attention to Pop Mart International Group (SEHK:9992) right now, recent price moves and financial figures offer a useful snapshot of how the market is treating the stock. See our latest analysis for Pop Mart International Group. At the latest share price of HK$207.4, the stock’s short term momentum looks softer, with a 7 day share price return of 9.75% and 30 day share price return of 12.56%, while the 1...

Government capital plan puts ICBC back in focus Industrial and Commercial Bank of China (SEHK:1398) has moved back into the spotlight after Beijing outlined a planned ¥300b capital injection into state owned banks through special treasury bonds and broader financial sector reforms. With investors watching how support may be allocated across the system, attention is turning to what this could mean for ICBC’s capital position, risk bearing capacity, and the way it manages exposure to property...

SINOPEC Engineering (Group) has announced that its board will meet on 13 March 2026 to review and approve the company’s 2025 annual results and consider a dividend distribution plan, which will later be submitted to shareholders at the annual general meeting. This upcoming board decision is important because it will pair fresh financial disclosures with a potential dividend proposal, giving investors clearer information on how the board is balancing capital returns and future investment...

If you are trying to figure out whether BYD’s current share price makes sense, you are in the right place. This article focuses on what the numbers say about value rather than the hype around electric vehicles. BYD last closed at HK$94.70, with returns of 5.2% over 30 days, a 19.1% decline over 1 year and gains of 45.6% over 3 years and 53.5% over 5 years. This gives a mixed picture of recent price momentum and changing risk sentiment. Recent coverage around BYD has focused on its position...

China has imposed an urgent ban on diesel and gasoline exports by state oil giants, including China Petroleum & Chemical (Sinopec), in response to escalating geopolitical tensions involving the US, Israel, and Iran. The suspension affects shipments to regional buyers and could tighten fuel supplies across the Asia Pacific market. The move marks a major shift in operating flexibility for SEHK:386, which has been a key supplier of refined products to neighboring economies. For China Petroleum...

XtalPi Holdings (SEHK:2228) has outlined a plan to reach profitability in 2025. Management links the shift to tripled revenue and improved performance in core businesses. A multi billion dollar collaboration with DoveTree is cited as a key factor in the updated outlook. The company highlights gains from recent partnerships as part of its 2025 profitability plan. XtalPi Holdings operates at the intersection of technology and biopharma, focusing on drug discovery and related services. For...

NetEase (SEHK:9999) is shifting from a secondary to a dual-primary listing on the Hong Kong Stock Exchange. The new structure is expected to qualify the company for potential inclusion in the Stock Connect program. Mainland Chinese investors would gain direct access to NetEase shares traded in Hong Kong for the first time. NetEase runs a large online games and internet services business, with operations that span PC and mobile titles, online learning, and other digital platforms. The move...

China Longyuan Power Group (SEHK:916) caught investor attention after reporting February 2026 power generation figures, with overall output edging up, wind output softening, and solar capacity continuing to contribute a higher share. See our latest analysis for China Longyuan Power Group. That February update comes after a strong run in the share price, with a 30 day share price return of 15.36% and a year to date share price return of 17.75% at a latest share price of HK$7.96. The 1 year...

CARsgen Therapeutics Holdings (SEHK:2171) opened FY 2025 with first half revenue of C¥51.0 million and a basic EPS loss of C¥0.14, while trailing 12 month figures show revenue of C¥84.0 million and a basic EPS loss of C¥0.95. The company reported revenue of C¥6.3 million in 1H 2024, C¥33.1 million in 2H 2024 and C¥51.0 million in 1H 2025, with basic EPS losses of C¥0.63, C¥0.81 and C¥0.14 across those respective periods. Investors are likely to focus on how margins develop from here and how...

Billion Industrial Holdings (SEHK:2299) has called a board meeting for 16 March 2026 to approve its audited 2025 final results and to consider a potential final dividend, which is a key focus for income oriented investors. See our latest analysis for Billion Industrial Holdings. The recent announcement has come after a period where the 1 year total shareholder return of 8.9% contrasts with a weaker year to date share price return of a 4.5% decline. This hints that earlier momentum has cooled...

Harbour Centre Development (SEHK:51) FY 2025 earnings snapshot Harbour Centre Development (SEHK:51) has posted its FY 2025 first half results with revenue of HK$654 million and a basic EPS loss of HK$0.28, keeping the focus squarely on how efficiently the business is converting its top line into profits. The company’s revenue increased from HK$623 million in the first half of FY 2024 to HK$654 million in the latest half. Over the same period, basic EPS moved from a loss of HK$0.01 in the...

Without a specific news headline driving attention today, WH Group (SEHK:288) still offers plenty to consider for investors who follow the global pork and packaged meats space and its recent share price performance. See our latest analysis for WH Group. At a share price of HK$9.79, WH Group has seen a 17.25% 90 day share price return, alongside a 64.32% 1 year total shareholder return and a 191.55% 3 year total shareholder return, which suggests momentum has been strong over multiple...

Tencent Holdings overview after recent share moves Tencent Holdings (SEHK:700) has attracted fresh attention after recent share price moves, with the stock last closing at HK$519. Investors are weighing this level against the group’s current earnings and business mix. See our latest analysis for Tencent Holdings. While Tencent’s 3.4% 1 day share price return has caught attention, the stock’s 30 day and year to date share price returns of 7.0% and 16.7% declines suggest momentum has cooled,...

If you are wondering whether PetroChina's recent share price leaves any value still on the table, this article will walk through what the current market price might be implying. With the stock at HK$10.40 and returns of 9.0% over 7 days, 13.5% over 30 days, 22.1% year to date, 92.1% over 1 year and 202.1% over 3 years, PetroChina has clearly been on many investors' radar. Recent coverage around PetroChina has focused on its position in the energy sector and how investors are reacting to that...

Why InSilico Medicine Cayman TopCo is on investors’ radar today InSilico Medicine Cayman TopCo (SEHK:3696) has drawn fresh attention after recent trading, with the share price at HK$55.50 and short term returns under pressure even as its year to date performance remains positive. For investors tracking AI focused biotech names, this mix of recent weakness over the past week and month alongside a stronger year to date move raises questions about how the company’s business metrics line up with...

CStone Pharmaceuticals previously announced that the UK MHRA has granted a new indication for sugemalimab monotherapy in certain adult patients with unresectable stage III non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiotherapy. This adds to approvals by the European Commission and UK MHRA across multiple non-small cell lung cancer settings, potentially broadening sugemalimab’s clinical footprint in key international markets. We will now examine how...

Why RemeGen’s latest earnings matter for investors RemeGen (SEHK:9995) has just posted full year 2025 results, moving from a net loss to a net profit, with sales and earnings per share both higher than the previous year. See our latest analysis for RemeGen. That earnings turnaround appears to be reflected in the share price, with a 1-day share price return of 10.92% and a year-to-date share price return of 15.82%. The 1-year total shareholder return is also very large and suggests strong...

Innovent Biologics (SEHK:1801) is back in focus after China’s National Medical Products Administration approved a new indication for Jaypirca, its non covalent BTK inhibitor for previously treated CLL/SLL patients. See our latest analysis for Innovent Biologics. The Jaypirca update lands after a choppy few months for the stock, with a 1 day share price return of 6.18% lifting the share price to HK$83.3. The 90 day share price return shows a 9.46% decline, which contrasts with a very strong 1...